560 related articles for article (PubMed ID: 20835362)
1. HSV Recombinant Vectors for Gene Therapy.
Manservigi R; Argnani R; Marconi P
Open Virol J; 2010 Jun; 4():123-56. PubMed ID: 20835362
[TBL] [Abstract][Full Text] [Related]
2. HSV as a vector in vaccine development and gene therapy.
Marconi P; Argnani R; Berto E; Epstein AL; Manservigi R
Hum Vaccin; 2008; 4(2):91-105. PubMed ID: 18496918
[TBL] [Abstract][Full Text] [Related]
3. HSV-1-derived helper-independent defective vectors, replicating vectors and amplicon vectors, for the treatment of brain diseases.
Marconi P; Manservigi R; Epstein AL
Curr Opin Drug Discov Devel; 2010 Mar; 13(2):169-83. PubMed ID: 20205051
[TBL] [Abstract][Full Text] [Related]
4. HSV as a vector in vaccine development and gene therapy.
Marconi P; Argnani R; Epstein AL; Manservigi R
Adv Exp Med Biol; 2009; 655():118-44. PubMed ID: 20047039
[TBL] [Abstract][Full Text] [Related]
5. Engineering HSV-1 Vectors for Gene Therapy.
Goins WF; Huang S; Hall B; Marzulli M; Cohen JB; Glorioso JC
Methods Mol Biol; 2020; 2060():73-90. PubMed ID: 31617173
[TBL] [Abstract][Full Text] [Related]
6. HSV-1-derived recombinant and amplicon vectors for gene transfer and gene therapy.
Epstein AL; Marconi P; Argnani R; Manservigi R
Curr Gene Ther; 2005 Oct; 5(5):445-58. PubMed ID: 16250886
[TBL] [Abstract][Full Text] [Related]
7. Engineering HSV-1 vectors for gene therapy.
Goins WF; Huang S; Cohen JB; Glorioso JC
Methods Mol Biol; 2014; 1144():63-79. PubMed ID: 24671677
[TBL] [Abstract][Full Text] [Related]
8. Gene delivery using herpes simplex virus vectors.
Burton EA; Fink DJ; Glorioso JC
DNA Cell Biol; 2002 Dec; 21(12):915-36. PubMed ID: 12573050
[TBL] [Abstract][Full Text] [Related]
9. Medical application of herpes simplex virus.
Watanabe D
J Dermatol Sci; 2010 Feb; 57(2):75-82. PubMed ID: 19939634
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
11. Spread and replication of and immune response to gamma134.5-negative herpes simplex virus type 1 vectors in BALB/c mice.
Broberg EK; Peltoniemi J; Nygårdas M; Vahlberg T; Röyttä M; Hukkanen V
J Virol; 2004 Dec; 78(23):13139-52. PubMed ID: 15542666
[TBL] [Abstract][Full Text] [Related]
12. A limited innate immune response is induced by a replication-defective herpes simplex virus vector following delivery to the murine central nervous system.
Zeier Z; Aguilar JS; Lopez CM; Devi-Rao GB; Watson ZL; Baker HV; Wagner EK; Bloom DC
J Neurovirol; 2009 Sep; 15(5-6):411-24. PubMed ID: 20095947
[TBL] [Abstract][Full Text] [Related]
13. Replication-Competent Controlled Herpes Simplex Virus.
Bloom DC; Feller J; McAnany P; Vilaboa N; Voellmy R
J Virol; 2015 Oct; 89(20):10668-79. PubMed ID: 26269179
[TBL] [Abstract][Full Text] [Related]
14. Replication-competent herpes simplex vectors: design and applications.
Argnani R; Lufino M; Manservigi M; Manservigi R
Gene Ther; 2005 Oct; 12 Suppl 1():S170-7. PubMed ID: 16231051
[TBL] [Abstract][Full Text] [Related]
15. [Herpes simplex type-1 virus-based vectors for gene therapy].
Ichikawa T; Saeki Y; Tamiya T; Chiocca EA; Ohmoto T
Nihon Rinsho; 2000 Apr; 58(4):822-7. PubMed ID: 10774201
[TBL] [Abstract][Full Text] [Related]
16. Herpes simplex virus 1 (HSV-1) for cancer treatment.
Shen Y; Nemunaitis J
Cancer Gene Ther; 2006 Nov; 13(11):975-92. PubMed ID: 16604059
[TBL] [Abstract][Full Text] [Related]
17. Safety of non-replicative and oncolytic replication-selective HSV vectors.
Epstein AL; Rabkin SD
Trends Mol Med; 2024 Jun; ():. PubMed ID: 38886138
[TBL] [Abstract][Full Text] [Related]
18. Construction and production of recombinant herpes simplex virus vectors.
Goins WF; Krisky DM; Wechuck JB; Huang S; Glorioso JC
Methods Mol Biol; 2008; 433():97-113. PubMed ID: 18679619
[TBL] [Abstract][Full Text] [Related]
19. Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo.
Anesti AM; Simpson GR; Price T; Pandha HS; Coffin RS
BMC Cancer; 2010 Sep; 10():486. PubMed ID: 20836854
[TBL] [Abstract][Full Text] [Related]
20. In situ cancer vaccination: an IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity.
Toda M; Martuza RL; Kojima H; Rabkin SD
J Immunol; 1998 May; 160(9):4457-64. PubMed ID: 9574551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
